Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2019-07-24 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시)(제3자배정 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from a Korean company (Lumi Micro) detailing the results of a third-party capital increase (share issuance). It specifies the number of shares issued, the amount raised, and the entities involved in the acquisition. This falls under the category of share issuance and capital changes.
2019-07-24 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a decision for a third-party capital increase (유상증자결정) by Lumi Micro Co., Ltd. This type of filing is a regulatory disclosure concerning changes in capital structure, specifically the issuance of new shares. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the appropriate category for announcements regarding new share issues and capital changes.
2019-07-08 Korean
조회공시요구(풍문또는보도)에대한답변(미확정)
Regulatory Filings Classification · 95% confidence The document is a regulatory response to a 'request for disclosure' (조회공시요구) regarding rumors of a merger (합병 추진설) with Dynona Co., Ltd. It provides an update on the status of the merger discussions, confirming that it remains 'undetermined' (미확정) and outlines the timeline for future updates. Since this is a regulatory disclosure regarding corporate activity (merger rumors) and does not fit into specific categories like M&A definitive agreements or financial reports, it is classified as a general regulatory filing.
2019-06-10 Korean
유상증자결정(종속회사의주요경영사항)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding a decision to issue new shares (capital increase) by a subsidiary of the company. It details the number of shares, the purpose of the funds (operating capital), the issuance method (shareholder allocation), and the board resolution date. This falls under the category of share issuance and capital changes.
2019-05-20 Korean
타법인주식및출자증권취득결정
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory filing from a Korean company (Lumi Micro) announcing the acquisition of shares in another entity (Lumi Technology & Loan). This type of disclosure, detailing the acquisition of equity in a subsidiary, is a standard corporate action announcement. In the context of the provided categories, this fits best under 'Regulatory Filings' (RNS) as it is a specific corporate disclosure regarding investment activity that does not fall into the more specialized categories like M&A (which usually implies external takeovers) or Share Issue (which focuses on the issuer's own capital structure).
2019-05-20 Korean
분기보고서 (2019.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Lumimicro Co., Ltd. for the period ending March 31, 2019. It contains detailed financial statements, management discussion, and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2019
2019-05-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.